Combination Twist1 and CA15-3 in axillary lymph nodes for breast cancer prognosis

Jiang,Xiaowei; Guo,Dan; Li,Wenfang; Yu,Tianwu; Zhou,Jian; Gong,Jianping

doi:10.3892/mmr.2017.6138

Combination Twist1 and CA15-3 in axillary lymph nodes for breast cancer prognosis

Authors:
- Xiaowei Jiang
- Dan Guo
- Wenfang Li
- Tianwu Yu
- Jian Zhou
- Jianping Gong
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China, Department of Breast Gland Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China, Department of General Surgery, Affiliated Yong Chuan Hospital of Chongqing Medical University, Chongqing 402160, P.R. China
Published online on: January 23, 2017 https://doi.org/10.3892/mmr.2017.6138
Pages: 1123-1134
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Twist1 overexpression is involved in epithelial‑mesenchymal transition resulting in migration and metastasis of breast cancer. Carcinoma antigen 15‑3 (CA15‑3) is widely used to monitor the prognosis for patients after treatment. However, the significance of Twist1 in axillary lymph nodes (ALN) and CA15‑3 for co‑examination for survival rates remains to be elucidated. The present study aimed to explore the role of the combination of Twist1 expression in metastasized ALN and the serum level of CA15‑3 in evaluating the prognosis of patients with breast cancer. cluster of differentiation (CD)44, CD24, aldehyde dehydrogenase (ALDH)1 and Twist1 expression in normal and metastasized ALN from 102 patients with breast cancer were detected using laser confocal microscopy and the expression of the genes evaluated by reverse transcription‑quantitative polymerase chain reaction; E‑cadherin, N‑cadherin and vimentin expression was also tested by western blotting. The serum concentrations of CA15‑3 prior to and following surgery were analyzed by chemiluminescence immunoassay. The expression of CD44, ALDH1 and Twist1 mRNA in the primary breast cancer tissues and involved ALN was upregulated compared with the normal ALN (P<0.05). The proteins N‑cadherin and vimentin of the involved ALN were poorly expressed compared with breast cancer tissues, however E‑cadherin protein expression was higher in metastasized and normal ALN compared with primary cancer tissues (P<0.05). Of the 102 patients, the serum CA15‑3 levels of the patients in stages I and II were significantly lower compared with stages III and IV (P<0.05). Twist1+/CA15‑3+, HER2-negative/Twist1+/CA15‑3+ and Triple‑receptor negative/Twist1+/CA15‑3+ groups displayed a shorter progression‑free survival compared with others. The results of the present study demonstrated that CD44, ALDH1 and Twist1 were significantly overexpressed in involved ALN. The serum levels of CA15‑3 in those patients were clearly increased and the survival rates decreased, which suggested that a combination of Twist1 in ALN and CA15‑3 may function as an indicator for the prognosis of patients with breast cancer.

View Figures

View References

1	Velasco-Velázquez MA, Homsi N, De La Fuente M and Pestell RG: Breast cancer stem cells. Int J Biochem Cell Biol. 44:573–577. 2012. View Article : Google Scholar : PubMed/NCBI
2	Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B and Menendez JA: Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle. 9:3807–3814. 2010. View Article : Google Scholar : PubMed/NCBI
3	Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
4	Li J and Zhou BP: Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 11:492011. View Article : Google Scholar : PubMed/NCBI
5	Ru GQ, Wang HJ, Xu WJ and Zhao ZS: Upregulation of twist in gastric carcinoma associated with tumor invasion and poor prognosis. Pathol Oncol Res. 17:341–347. 2011. View Article : Google Scholar : PubMed/NCBI
6	Li S, Kendall SE, Raices R, Finlay J, Covarrubias M, Liu Z, Lowe G, Lin YH, Teh YH, Leigh V, et al: TWIST1 associates with NF-κB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production. BMC Biol. 10:732012. View Article : Google Scholar : PubMed/NCBI
7	Kong Y, Wang J, Liu W, Chen Q, Yang J, Wei W, Wu M, Yang L, Xie X, Lv N, et al: Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients. PLoS One. 8:e570922013. View Article : Google Scholar : PubMed/NCBI
8	Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L and Yang J: Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 19:372–386. 2011. View Article : Google Scholar : PubMed/NCBI
9	Qin Q, Xu Y, He T, Qin C and Xu J: Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res. 22:90–106. 2012. View Article : Google Scholar : PubMed/NCBI
10	Sleeman JP, Cady B and Pantel K: The connectivity of lymphogenous and hematogenous tumor cell dissemination: Biological insights and clinical implications. Clin Exp Metastasis. 29:737–746. 2012. View Article : Google Scholar : PubMed/NCBI
11	Markiewicz A, Ahrends T, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Jaśkiewicz J, Szade J, Biernat W and Zaczek AJ: Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med. 10:2262012. View Article : Google Scholar : PubMed/NCBI
12	Sell S: Cancer-associated carbohydrates identified by monoclonal antibodies. Hum Pathol. 21:1003–1019. 1990. View Article : Google Scholar : PubMed/NCBI
13	Hilkens J, Buijs F, Hilgers J, Hageman P, Calafat J, Sonnenberg A and van der Valk M: Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer. 34:197–206. 1984. View Article : Google Scholar : PubMed/NCBI
14	Duffy MJ, Evoy D and McDermott EW: CA 15–3: Uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 411:1869–1874. 2010. View Article : Google Scholar : PubMed/NCBI
15	Zhou J, Zhang L, Gu Y, Li K, Nie Y, Fan D and Feng Y: Dynamic expression of CEACAM7 in precursor lesions of gastric carcinoma and its prognostic value in combination with CEA. World J Surg Oncol. 9:1722011. View Article : Google Scholar : PubMed/NCBI
16	Sobin LH, Hermanek P and Hutter RV: TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer. 61:2310–2314. 1988. View Article : Google Scholar : PubMed/NCBI
17	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
18	Montgomery N, Hill A, McFarlane S, Neisen J, O'Grady A, Conlon S, Jirstrom K, Kay EW and Waugh DJ: CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res. 14:R842012. View Article : Google Scholar : PubMed/NCBI
19	Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
20	Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 106:13820–13825. 2009. View Article : Google Scholar : PubMed/NCBI
21	Zhong Y, Shen S, Zhou Y, Mao F, Guan J, Lin Y, Xu Y and Sun Q: ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype. Med Oncol. 31:8642014. View Article : Google Scholar : PubMed/NCBI
22	Sung WJ, Park KS, Kwak SG, Hyun DS, Jang JS and Park KK: Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: Correlation with cancer stem cell markers and prognosis. Int J Clin Exp Pathol. 8:8997–9009. 2015.PubMed/NCBI
23	Vesuna F, Lisok A, Kimble B and Raman V: Twist modulates breast cancer stem cells by transcriptional. Neoplasia. 11:1318–1328. 2009. View Article : Google Scholar : PubMed/NCBI
24	Li J and Zhou BP: Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 11:492011. View Article : Google Scholar : PubMed/NCBI
25	Kalluri R: EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 119:1417–1419. 2009. View Article : Google Scholar : PubMed/NCBI
26	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
27	Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
28	Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, Groep P vander, Artemov D, Kowalski J, Carraway H, van Diest P and Raman V: Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. Oncogene. 31:3223–3234. 2012. View Article : Google Scholar : PubMed/NCBI
29	Ri G, Ohno S, Yamamoto T, Ito E, Furutani M, Furutani Y, Umeda Y, Tsukahara T, Hagita N and Matsuoka R: Serum levels of CA15-3, KL-6 and BCA225 are positively correlated with each other in the general population. Anticancer Res. 29:4239–4242. 2009.PubMed/NCBI
30	Bidard FC, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Cottu P, Beuzeboc P, Rolland E, Mathiot C and Pierga JY: Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: A prospective observational study. Breast Cancer Res. 14:R292012. View Article : Google Scholar : PubMed/NCBI